Cantor Fitzgerald initiated coverage of Crispr Therapeutics with an Overweight rating and $72 price target. The analyst says Crispr "stands out" as an "interesting" gene editing play for 2023. The company has a "very good chance" of commercializing the first-ever CRISPR gene therapy later this year, the analyst tells investors in a research note. The firm likes the stock’s risk/reward setup for "what should be a very busy and transformational year" for the company.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- CRISPR Surges 16% as Cantor Fitzgerald Assigns $72 PT
- CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
- Crispr Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Vertex Pharmaceuticals, Crispr Therapeutics complete rolling BLAs to FDA
- Bluebird Bio reaction to lovo-cel BLA delay ‘overdone,’ says Raymond James
